· Published by Health Canada · Official notice
This is duplicated text of a letter from Mylan Pharmaceuticals ULC. Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
September 22, 2014
Dear Health Care Professional,
Subject: Some Mylan-Nitro Sublingual Spray 0.4 mg Per Metered Dose (DIN: 02243588) canisters may be missing dip tubes
Mylan Pharmaceuticals ULC, in consultation with Health Canada, wants to inform you of a manufacturing issue which could cause some of Mylan’s Nitro-Sublingual Spray canisters to stop delivering medication, due to a missing dip tube in the pump valve assembly. This could, in turn, lead to a patient not receiving a dose of medicine when needed. Mylan has determined that the potential frequency of the missing dip tubes is very low, and no such issue has been reported by consumers to date.
An initial decision was made to recall this product due to the possibility of a failed dose and the potential risk to the patient. Subsequent to the decision to recall all lots of the product and the posting of a Public Advisory on the Health Canada website advising of the recall, Mylan became aware of additional information concerning the potential for a shortage of nitro sublingual spray. While this continues to remain a recall situation, in view of the potential for a drug shortage, and to provide patients with ongoing access to a medically necessary product, Mylan Pharmaceuticals ULC has proposed the following steps as a short-term interim approach to meet patients’ needs. Based on the information received to date, Health Canada accepted this as an interim strategy while Mylan urgently investigates other options to stabilize supply of Mylan-Nitro Sublingual Spray.
Mylan Pharmaceuticals ULC continues to work on resolving this issue as quickly as possible and resuming regular product supply. Health Canada will continue to work with the company and monitor the situation to help ensure that patients and healthcare professionals are informed. Mylan Pharmaceuticals ULC will issue a new communication letter to inform you immediately when the situation has been fully resolved. Once the supply has been stabilized and unaffected product becomes available, remaining product from the affected lots will be removed from the market.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious adverse reactions, or unexpected adverse reactions in patients receiving Mylan-Nitro Sublingual Spray 0.4 mg per metered dose should be reported to Mylan Pharmaceuticals ULC or Health Canada.
Mylan Pharmaceuticals ULC
85 Advance Road, Etobicoke, ON
M8Z 2S6
Mylan ULC Customer Relations
Phone: 1-800-575-1379
Fax: 1-855-236-2990
E-mail: customerservice@mylan.ca
To correct your mailing address or fax number, contact Mylan Pharmaceuticals ULC.
You can report any suspected adverse reactions associated with the use of health products to Health Canada by:
For other health product inquiries related to this communication, please contact Health Canada at:
Health Products and Food Branch Inspectorate
E-mail: DCVIU_UVCEM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 613-946-5636
Sincerely,
original signed by
Anca Schmidt
Senior Director, Quality
Mylan Pharmaceuticals ULC